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s.neggers@erasmusmc.nlAbstractObjective: To evaluate extended dosing intervals (EDIs) with lanreotide Autogel 120 mg in patients with acromegaly
previously biochemically controlled with octreotide LAR 10 or 20 mg.
Design and methods: Patients with acromegaly had received octreotide LAR 10 or 20 mg/4 weeks for R6 months and had
normal IGF1 levels. Lanreotide Autogel 120 mg was administered every 6 weeks for 24 weeks (phase 1); depending on week-
24 IGF1 levels, treatment was then administered every 4, 6 or 8 weeks for a further 24 weeks (phase 2). Hormone levels,
patient-reported outcomes and adverse events were assessed. Primary endpoint: proportion of patients on 6- or 8-week EDIs
with normal IGF1 levels at week 48 (study end).
Results: 107/124 patients completed the study (15 withdrew from phase 1 and two from phase 2). Of 124 patients enrolled,
77.4% were allocated to 6- or 8-week EDIs in phase 2 and 75.8% (95% CI: 68.3–83.3) had normal IGF1 levels at week 48 with
the EDI (primary analysis). A total of 88.7% (83.1–94.3) had normal IGF1 levels after 24 weeks with 6-weekly dosing. GH levels
were%2.5 mg/l inO90% of patients after 24 and 48 weeks. Patient preferences for lanreotide Autogel 120 mg every 4, 6 or
8 weeks over octreotide LAR every 4 weeks were high.
Conclusions: Patients with acromegaly achieving biochemical control with octreotide LAR 10 or 20 mg/4 weeks are possible
candidates for lanreotide Autogel 120 mg EDIs. EDIs are effective and well received among such patients.ice
.0 UEuropean Journal of
Endocrinology
(2015) 173, 313–323nsed under a Creative Commons
nported License.
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173 :3 314IntroductionAcromegaly is an uncommon disease that is almost always
due to a benign pituitary tumour and which is characterized
by increased levels of growth hormone (GH) and insulin-
like growth factor-1 (IGF1). The hormonal imbalance leads
to multiple significant comorbidities – particularly cardio-
vascular complications, diabetes mellitus, bone and joint
disease and sleep apnoea (1) – and an increased mortality
rate (2). Medical therapy, one approach for the treatment of
acromegaly, is usually recommended for patients for whom
pituitary surgery was not curative or for whom a surgical
approach was contraindicated or refused (1). For these
patients, the first-line medical treatment is generally a long-
acting somatostatin analogue (3, 4), such as lanreotide
Autogel (known as lanreotide Depot in the USA), which has
been shown to reduce GH and IGF1 excesses and pituitary
tumour volume, ameliorate symptoms and improve health-
related quality of life (HRQoL) (5, 6, 7). It has also been
suggested in a meta-analysis that mortality rates are reduced
by high biochemical remission rates and the use of
somatostatin analogues (8).
As chronic therapy will be required for most patients
receiving somatostatin analogues, it is important to
consider how to optimize treatment acceptability. Some
patients may be able to reduce the burden of frequent clinic
visits by taking advantage of the pre-filled ready-to-use
syringes available with lanreotide Autogel and administer
treatment by self- or partner injection (where home
administration is approved, such as in Europe) (9, 10, 11).
The ready-to-use mode of administration for lanreotide can,
when provided by healthcare practitioners (HCPs; as in the
USA), provide time savings for improving other aspects of
patient care (12). The burden of frequent clinic visits could
also be reduced if, as advocated by the Acromegaly
Consensus Group, individuals achieving good biochemical
control with long-acting somatostatin analogues received
treatment less frequently (3). Pharmacologically effective
levels of lanreotide are sustained beyond the standard
4-week dosing interval (13), and initial studies indicate that
some patients may thus be able to switch to 6- or 8-weekly
dosing intervals without loss of efficacy (14, 15). While
benefiting patients, both self-/partner or HCP injections
togetherwith extended dosing intervals (EDIs) alsohave the
potential to reduce the economic burden of the disease.
Currently, lanreotide Autogel is the only long-acting
somatostatin analogue to have been approved for use with
EDIs (both in Europe and the USA).
The Lanreotide Extended Autogel Duration (LEAD)
study was a large international clinical trial evaluating thewww.eje-online.orgefficacy, safety and patient-reported outcomes (PROs) of
6- and 8-week EDIs with lanreotide Autogel 120 mg in
patients with acromegaly previously biochemically con-
trolled with 10 or 20 mg of octreotide LAR every 4 weeks.Patients and methods
Patients
Patients eligible for the study were adults (agedO18 years)
who had been diagnosed with acromegaly on the basis of
elevated IGF1 and/or GH levels. Patients had additionally
received octreotide LAR 10 or 20 mg every 4 weeks forR6
months previously and achieved normal (age- and sex-
adjusted) IGF1 levels on two consecutive occasions
(separated by an interval of R2 months). For patients
receiving concomitant dopamine agonist therapy, treat-
ment was stable for R4 months, with no change in
dopamine-agonist medication expected during the study.
Patients were excluded from the study if they had
received any previous pituitary radiation therapy, they
were likely to require pituitary surgery or radiation therapy
during the study, or they had received GH receptor
antagonist treatment within the previous 3 months.
Eligible patients could not have abnormal laboratory
findings or medical conditions that may have jeopardized
their safety or interfered with the study, or a history of
hypersensitivity to lanreotide or drugs with similar
chemical structure, and they could not have used an
unlicensed drug in the previous 30 days. Women were
excluded if they were not using acceptable methods of
contraception or were pregnant or lactating.
Patients were withdrawn from the study at any time if
there was evidence of worsening acromegalic symptoms
requiring treatment other than lanreotide Autogel, signs
of tumour progression requiring surgery or at the
discretion of investigators for safety reasons. Patients
could also withdraw consent at any time.Trial design and interventions
The LEAD study was an open-label, non-comparative trial
conducted between October 6, 2008 and May 20, 2013 in
14 countries (Brazil, Denmark, Finland, France, Greece,
Latvia, The Netherlands, Norway, Poland, Romania,
Russia, Serbia, South Korea, and Sweden). There were
two 24-week phases in the study (Fig. 1). In phase 1,
patients received five injections of lanreotide Autogel
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173 :3 315120 mg (Beaufour Ipsen Industrie, Dreux, France) with a
6-week EDI. In phase 2, patients received further injections
of lanreotide Autogel 120 mg with a 4-week dosing
interval, or 6- or 8-week EDI depending on their IGF1
levels at the end of phase 1. Patients with IGF1 levels
O130% of the upper limit of normal (ULN) at the end
of phase 1 did not continue into phase 2. Lanreotide
Autogel was administered by deep subcutaneous injection.
Injections at baseline and week 24 were administered at
the study centre; other injections could be administered in
the patient’s home as part of the patient’s regular care.
Before the study started, the protocol, its amend-
ments, the consent form, the study questionnaires and the
patient information leaflet were approved by independent
ethics committees in each country. The trial was con-
ducted in accordance with the Declaration of Helsinki,
Good Clinical Practice guidelines and all local regulatory
requirements and it was registered with EudraCT
(2007-005838-37) and ClinicalTrials.gov (NCT00701363).
All patients provided written informed consent before
participating in the study.Assessments
Study visits were scheduled at baseline (week 0), at
6-weekly intervals in phase 1 (up to week 24), and
according to the dosing interval to which patients
were assigned in phase 2 (up to week 48) (Fig. 1).Phase 1 P
IGF1 >13
Withdrawn from
Timing of injections (weeks)
0 6
Start 6-weekly injections
Patients with biochemically controlled
acromegaly (normal IGF1) previously
receiving octreotide LAR 10/20 mg every
4 weeks for ≥6 months
12 18 24
Figure 1
Study design and schedule for treatment with lanreotide Autogel
dosing interval; IGF1, insulin-like growth factor-1; ULN, upper limitThe end-of-study visit was scheduled at week 48; patients
discontinuing prematurely from the study attended an
early withdrawal visit.
Hormone levels were determined centrally from blood
samples taken under fasting conditions at baseline, and
at the end of phases 1 and 2 (or at early withdrawal,
if applicable). IGF1 levels were assessed from single
samples using a solid-phase enzyme-labelled chemilumi-
nescent immunometric assay (Immulite 2000 IGF1/
Siemens Healthcare Diagnostics, Los Angeles, CA, USA)
with an analytical sensitivity of 20 mg/l, intra-assay precision
of 2.3–3.9% and interassay precision of 3.7–8.1%. Multiple
batches rather than a single batch of the Immulite assay
were used to test the samples. In addition, due to supply
difficulties with this IGF1 assay towards the end of the
study, IGF1 levels for five samples (three patients) were
assessed using the iSYS IGF1 immunoassay (Immunodiag-
nostic Systems, Boldon, UK). Comparison of the two
methods (scatterplot with regression analysis) showed that
the IGF1 levels were highly consistent between the two
assays up to 200 mg/l. As the range of IGF1 levels across the
five samples assessed with the iSYS assay was 85–188 mg/l,
neither sensitivity nor post hoc analyses were considered
necessary. GH levels were assessed from three samples
taken at 1-h intervals using a simultaneous one-step
immunoenzymatic assay (Access Ultrasensitive hGH,
Beckman Coulter, Inc., Nyon, Switzerland). The GH
assay had a lower limit of detection of 0.004 mg/l,hase 2
28
30
0%
 the study
Study end
(week 48)
36 42
32
32 40
IGF1 >50% to ≤100% ULN
Continue 6-weekly injections (6-week EDI)
IGF1 ≤50% ULN
Change to 8-weekly injections (8-week EDI)
IGF1 >100% to ≤130% ULN
Change to 4-weekly injections (4-week DI)
36 40 44
120 mg in the LEAD study. DI, dosing interval; EDI, extended
of normal.
www.eje-online.org
128 patients screened
4 patients excluded (did not meet
inclusion criteria)
124 patients entered phase 1 (6-week dosing)
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173 :3 316intra-assay precision of 1.9–3.8% and interassay precision
of 2.4–3.9%.
The PROs measured were symptom severity, HRQoL
and treatment preference. The patient-assessed acrome-
galy symptom questionnaire (PASQ) was used to report the
severity of five symptoms and signs of acromegaly at
baseline and at the end of phases 1 and 2 (severity scale
ranged from 0 (no symptoms) to 8 (severe, incapacitating
symptoms); symptoms and signs assessed were headache,
excessive perspiration, fatigue, soft tissue swelling and
arthralgia) (16). PASQ symptoms and signs were also
recorded as adverse events (AEs) if they were considered
serious. HRQoL was assessed with the AcroQoL
questionnaire (17) and the SF-36v2w health survey (18);
these were completed by patients at baseline and at the
end of phases 1 and 2 (patients from Finland, Latvia and
Serbia did not complete the AcroQoL questionnaire as
validated translations were not available). Scores ranged
from 0 (worst possible HRQoL) to 100 (best possible
HRQoL). Patients were asked by the investigators to state
their treatment preferences for lanreotide Autogel vs
octreotide LAR at the end of phases 1 and 2.
Safety assessments comprised: AEs collected through-
out the study; physical examination, vital signs, haema-
tology and biochemistry assessed at baseline and at the
end of phases 1 and 2 (or early withdrawal, if applicable);
and gallbladder ultrasound performed at baseline and at
the end of phase 2 (or early withdrawal).15 patients withdrew prematurely:
7 due to AEs
5 withdrew consent
13 allocated to 4-week DI
26 allocated to 8-week EDI
2 withdrew prematurely
(6-week EDI group):
1 due to an AE
1 withdrew consent
107 patients completed the study
70 allocated to 6-week EDI
1 protocol violation
1 did not meet entry criteria
1 lack of efficacy
(ITT and safety populations)
109 patients entered phase 2
(modified ITT population):
Figure 2
Flow of patients through the study. AE, adverse event; DI,
dosing interval; EDI, extended dosing interval; ITT, intention to
treat.Endpoints
The primary endpoint was the proportion of patients who
were on the 6- or 8-week EDI and had a normal IGF1 level
at week 48 (study end). Related secondary endpoints were
the proportion of patients who had a normal IGF1 level on
the 6-week EDI at week 24 (end of phase 1), the proportion
who were on the 8-week EDI and had a normal IGF1 level
at week 48, and the proportion who were on the 6- or
8-week EDI (regardless of IGF1 level) at week 48. Other
secondary endpoints based on IGF1 levels were: IGF1 level
changes from baseline to week 48 overall and by dosing-
interval group; baseline IGF1 levels for patients with
normal IGF1 levels at week 48 by dosing-interval group;
and baseline IGF1 levels for patients with vs without
normal IGF1 levels at week 24.
Secondary endpoints based on GH control were:
proportions of patients with GH levels %2.5 mg/l at
weeks 24 and 48, and GH levels at baseline and weeks 24
and 48. These a priori endpoints were supplemented
post hoc by the proportions of patients with GH levelswww.eje-online.org!1.0 mg/l and the proportions with GH levels %2.5 mg/l
and a normal IGF1 level at week 24.
Other secondary endpoints included: PASQ scores at
baseline and weeks 24 and 48 (the end of phases 1 and 2);
changes in HRQoL scores (AcroQoL global score and
SF-36v2w physical (PCS) and mental (MCS) component
summary scores) at week 24 and 48; the proportion of
patients with normal IGF1 levels and no deterioration
in AcroQoL global score (deterioration defined as a
decrease of at least one point from baseline) at week 48;
the correlation between AcroQoL global score changes
and IGF1 level (% of ULN) changes at weeks 24 and 48;
treatment preferences at weeks 24 and 48; and safety.
In accordance with guidelines for the use of the SF-36v2w
health survey, the a priori analysis using a total score was
replaced post hoc by two separate analyses using PCS
and MCS scores.Statistical analysis
The proportion of patients entering the study who were
on a 6- or 8-week EDI with a normal IGF1 level at week 48
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173 :3 317(primary endpoint) was initially assumed to be 50%.
Following an interim review of the data, the point estimate
of this proportion was revised to 70%. Accordingly, a
corrected total of 127 patients were needed to estimate
this revised proportion with a precision ofG8.0% based on
a two-sided 95% CI.
The primary analysis for the primary endpoint was
based on the intention-to-treat (ITT) population, which
was defined as all patients who received at least one
injection (i.e., patients entering into phase 1 regardless of
whether or not they entered phase 2). Supportive analyses
for the primary endpoint were based on the modified ITT
population (patients from the ITT population who were
allocated to a phase-2 dosing interval group) and the
per-protocol (PP) population (patients from the ITT
population without major protocol deviations). Analyses
of between-group differences in IGF1 levels in phase 2
were based on the modified ITT population. All other
secondary efficacy analyses were based on both ITT and
modified ITT populations and results were similar in all
cases; thus, only data from analyses on the ITT population
are reported. Missing data were not replaced, but last post-
baseline value available assessments were calculated for all
efficacy endpoints. Safety analyses were based on the
safety population (defined as per the ITT population).
Between-group comparisons of mean IGF1 levels were
performed using either an analysis of covariance with
injection interval group as the main factor and baseline
IGF1 level as the covariate (changes in IGF1 levels) or a
student’s t-test (baseline IGF1 levels). CorrelationsTable 1 Baseline demographic and disease characteristics. Data a
mean (S.D.) unless specified otherwise.
Phase 1 onlya
(6-week EDI) (nZ15) 4-week DI (nZ13
Age (years) 55.2 (15.3) 55.0 (10.1)
Men:women, n (%) 6 (40.0):9 (60.0) 5 (38.5):8 (62.
BMI (kg/m2) 28.4 (2.9) 29.2 (4.1)
Time from diagnosis (years) 6.9 (5.3) 10.2 (5.9)
Time since surgery (years) (nZ10) (nZ10)
6.3 (4.3) 9.6 (6.0)
Octreotide LAR treatment:
duration (years)
(nZ14) (nZ13)
2.2 (2.2) 2.5 (2.4)
Dose, n (%)
10 mg 4 (28.6) 0
20 mg 10 (71.4) 13 (100)
IGF1 level (% ULN) (nZ15) (nZ12)
93.3 (76.7) 98.7 (14.6)
GH level (mg/l)b 1.0 (1.0) 0.9 (0.7)
DI, dosing interval; EDI, extended dosing interval; GH, growth hormone; IGF1,
aPatients from phase 1 not entering phase 2.
bGH levels assessed by local laboratories.between HRQoL (AcroQoL score) and IGF1 level changes
were examined using a non-parametric Spearman corre-
lation test. Descriptive statistics were used for safety and
other secondary efficacy endpoints. Statistical analyses
were performed using SAS software version 9.2 or higher
(SAS Institute, Inc., Cary, NC, USA).Results
Patient disposition and baseline characteristics
A total of 124 patients entered phase 1 of the study and
received treatment (ITT/safety population). Of these,
15 patients were withdrawn prematurely during phase 1
(including one patient withdrawn because of a lack of
efficacy) (Fig. 2). Of 109 patients entering phase 2
(modified ITT population), 107 completed the study. The
PP population (nZ118) excluded two patients with
violation of the inclusion criteria, two with missing IGF1
measurements at week 24, one who had received out-
of-date study medication and one who had received a
prohibited therapy (dose of dopamine agonist changed
during the study). Of 124 patients enrolled, 96 (77.4%)
were allocated to 6- or 8-week EDIs in phase 2.
Baseline demographic and disease characteristics were
generally well balanced among the final dosing-interval
groups, except for a slightly higher proportion of women
in the 8-week EDI group compared with the 4-week
dosing-interval and 6-week EDI groups (Table 1). The
mean (S.D.) duration of previous treatment with octreotidere from the intention-to-treat population and are expressed as
Phase 2
All patients
(nZ124)) 6-week EDI (nZ70) 8-week EDI (nZ26)
53.2 (10.4) 57.0 (9.8) 54.4 (10.9)
5) 29 (41.4):41 (58.6) 6 (23.1):20 (76.9) 46 (37.1):78 (62.9)
29.5 (6.5) 27.0 (4.3) 28.8 (5.6)
8.2 (5.3) 10.2 (7.4) 8.7 (5.9)
(nZ54) (nZ24) (nZ98)
7.6 (4.3) 9.2 (7.3) 8.1 (5.4)
(nZ70) (nZ26) (nZ123)
2.6 (2.4) 2.5 (1.8) 2.5 (2.2)
11 (15.7) 9 (34.6) 24 (19.5)
59 (84.3) 17 (65.4) 99 (80.5)
(nZ70) (nZ26) (nZ123)
67.7 (29.6) 52.5 (25.0) 70.6 (39.2)
0.9 (1.2) 1.1 (1.2) 1.0 (1.1)
insulin-like growth factor-1; ULN, upper limit of normal.
www.eje-online.org
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173 :3 318LAR was 2.5 (2.2) years and 80.5% of patients had been
receiving octreotide 20 mg (among patients in phase 2,
100, 84.3 and 65.4% in the 4-, 6- and 8-week dosing
groups, respectively, had been receiving octreotide LAR
20 mg before the study). Nine patients were receiving
concomitant dopamine agonists (bromocriptine, nZ6;
cabergoline, nZ3).Efficacy
IGF1 control and EDIs " In the primary analysis of the
primary endpoint, 94 of the 124 patients (75.8% (95% CI:
68.3–83.3)) in the ITT population were on a 6- or 8-week
EDI and had a normal IGF1 level at week 48 (end of study;100
(a)
(b)
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(n=12–13)
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LVAWeek
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Week
24
Baseline
Week 48
(n=124)
6- or 8-week
EDI
Primary endpoint
88.7
75.8
20.2
8-week
EDI
Figure 3
(a) Patients with normal IGF1 levels on EDIs at weeks 24 (end of
phase 1) and 48 (end of study). (b) Serum IGF1 levels (% of ULN)
according to allocated injection schedule for lanreotide
Autogel 120 mg in phase 2. Data are from the ITT population.
DI, dosing interval; EDI, extended dosing interval; IGF1,
insulin-like growth factor-1; ITT, intention to treat; LVA, last
post-baseline value available; ULN, upper limit of normal.
www.eje-online.orgFig. 3a). The supportive analysis based on the PP
population was similar to the primary analysis (PP
population: 92/118, 78.0% (70.5–85.4)), whereas the
supportive analysis based on the modified ITT population
was higher (modified ITT population: 94/109, 86.2%
(79.8–92.7)).
For the related IGF1 and EDI secondary endpoints, 110
of the 124 patients (88.7% (95% CI: 83.1–94.3)) in the ITT
population had a normal IGF1 level with the 6-week EDI at
week 24 (end of phase 1), 25/124 patients (20.2% (95% CI:
13.1–27.2)) on the most extended dosing schedule
(8 weeks) had a normal IGF1 level at week 48 (Fig. 3a) and
97/124 patients (78.2% (95% CI: 71.0–85.5)) were on a 6- or
8-week EDI at week 48 (regardless of IGF1 level). Within the
individual dosing-interval groups, normal IGF1 levels were
achieved at week 48 by 13/13 patients with a 4-week dosing
interval, 67/70 with the 6-week EDI and 25/26 with the
8-week EDI. Of the patients receiving concomitant
dopamine agonist treatment, 7/9 had a normal IGF1 level
at week 24; all seven patients receiving a concomitant
dopamine agonist and continuing into phase 2 were on a
6- or 8-week EDI at week 48 (four patients on the 6-week
schedule and three on the 8-week schedule).
Figure 3b shows serum IGF1 levels according to the
allocated injection interval schedule in phase 2.
Compared with the 4-week dosing-interval group,
adjusted mean changes in IGF1 levels (% ULN) from
baseline to week 48 were significantly better (smaller
increases or larger decreases) for the 6- or 8-week EDI
groups among patients with normalized IGF1 levels at
week 48 (4- vs 6-week: 18.7 (95% CI: 7.5–29.9), PZ0.0013;
4- vs 8-week: 42.7 (29.5–55.8), P!0.0001; Table 2).
Compared with the 4-week dosing-interval group, mean
baseline % ULN IGF1 levels were also significantly lower
in 6- and/or 8-week EDI groups in these patients (4- vs
6-week: 30.9 (13.1–48.8), PZ0.0009; 4- vs 8-week: 47.4
(31.7–63.1), P!0.0001; 4- vs 6- and 8-week: 35.1
(18.1–52.7), P!0.0001; Table 2). The mean (S.D.) baseline
% ULN IGF1 level at week 24 for patients who went into
phase 2 (i.e., with a normal IGF1 levels at week 24) was
significantly lower (67.5 (30.0) (nZ108)) than that for
patients without normalized IGF1 levels (95.9 (78.9)
(nZ14); mean (95% CI) difference: K28.4 (K50.0 to
K6.8), PZ0.0103).
GH control and combined IGF1 and GH control " Most
patients achieved GH control (%2.5 mg/l) and combined
IGF1 and GH control (normal IGF1 levels and GH levels
%2.5 mg/l) after 24 weeks of the 6-week EDI (i.e. end of
phase 1). Specifically, 105/112 patients with data available
Table 2 Differences between dosing-interval groups for IGF1 levels (% ULN) in patients with normalized levels at week 48
(end of study; secondary endpoints). Data are from the modified intention-to-treat population.
4-week DI
(nZ13)
6-week EDI
(nZ70)
8-week EDI
(nZ26)
Between-group differences
4-week DI vs 6-week
EDI
6-week EDI vs
8-week EDI
4-week DI vs
8-week EDI
4-week DI vs
6-C8-week EDI
Baselinea, mean
(S.D.)
(nZ12) (nZ67) (nZ25)
98.7 (14.6) 67.8 (30.3) 51.3 (24.7) 30.9 (13.1–48.8)‡ 16.5 (3.0–29.9)* 47.4 (31.7–63.1)‡ 35.1 (18.1–52.7)‡
Change from (nZ12) (nZ67) (nZ25)
baseline to
week 48b,
adjusted mean
(S.E.M.)
24.8 (5.3) 6.1 (2.1) K17.9 (3.5) 18.7 (7.5–29.9)† 24.0 (15.8–32.1)‡ 42.7 (29.5–55.8)‡ N/A
*P!0.05, †P!0.01, ‡P!0.001. DI, dosing interval; EDI, extended dosing interval; IGF1, insulin-like growth-factor 1; NA, not applicable; ULN, upper limit of
normal.
aBetween group differences are presented as mean (95% CI) using student’s t-test (two-sided).
bBetween group differences are presented as adjusted mean (95% CI) of the analysis of covariance with injection interval group as main factor and baseline
level as covariate.
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173 :3 319(93.8% (95% CI: 89.3–98.2)) had GH levels %2.5 mg/l
(Fig. 4a) and 103/112 (92.0% (86.9–97.0)) had both
normal IGF1 levels and GH levels%2.5 mg/l. The majority
of patients in phase 1 also achieved the more stringent
measure of GH control (!1.0 mg/l) at the same time
point (77/112 patients, 68.8% (60.2–77.3). Levels of GH
control remained high after a further 24 weeks (i.e., end
of phase 2) both within dosing-interval groups and for
phase-2 participants overall (Fig. 4a). Specifically, for
phase-2 patients overall at week 48, 101/107 patients
(94.4% (95% CI: 90.0–98.8)) had GH levels %2.5 mg/l.
Mean serum GH levels were relatively stable through-
out the study, particularly for the 6-week EDI group
(Fig. 4b).
Acromegaly symptoms and HRQoL " Mean (S.D.) total
PASQ symptom scores changed little between baseline
(12.9 (7.8)) and weeks 24 (12.8 (8.6)) and 48 (14.0 (8.5)).
Individual PASQ symptom scores were also generally
stable throughout the study (Supplementary Figure 1, see
section on supplementary data given at the end of this
article), and different dosing intervals had no clear effect
on PASQ symptom scores (data not shown).
Among patients completing the AcroQoL question-
naire (i.e., in countries in which validated translations
were available), adjusted mean changes from baseline to
weeks 24 and 48 in the global score were not significantly
different in pairwise comparisons of dosing-interval
groups (Supplementary Table 1, see section on supplemen-
tary data given at the end of this article). Of 83 patients
who had data for the global score at baseline and week 48,
37 had a normal IGF1 level at week 48 and a stable or
improved global score (44.6% (95% CI: 33.9–55.3)).Overall, there was no correlation between changes from
baseline to weeks 24 or 48 in the AcroQoL global score and
changes in IGF1 levels (Spearman correlation,K0.01 (95%
CI: K0.23 to 0.20) nZ85 and (K0.01 (K0.22 to 0.21)
nZ82, respectively).
Adjusted mean changes from baseline to weeks 24 and
48 in the MCS and PCS scores of the SF-36v2w were not
significantly different in pairwise comparisons of dosing-
interval groups (Supplementary Table 1).
Treatment preference " At week 24 (end of phase 1),
more patients preferred lanreotide Autogel 120 mg with a
6-week EDI than octreotide LAR every 4 weeks (lanreotide:
99/112 patients, 88.4% (95% CI: 82.5–94.3); octreotide:
10/112 patients, 8.9% (3.6–14.2); three patients had no
preference).
At week 48 (end of phase 2), almost all patients preferred
lanreotide Autogel 120 mg over octreotide LAR in the
8-week EDI group (24/26 patients, 92.3% (82.1–100.0) vs
2/26 patients, 7.7%(0.0–17.9) respectively). In the other two
groups, more than three-quarters of patients preferred
lanreotide Autogel 120 mg over octreotide LAR (6-week
EDI group: 53/68 patients, 77.9% (68.1–87.8) vs 10/68
patients 14.7% (6.3–23.1), respectively (one further patient
indicated a preference for lanreotide 4-week dosing interval
and four patients had no preference); 4-week dosing
interval: 10/13 patients, 76.9% (54.0–99.8) vs 2/13 patients,
15.4% (0.0–35.0) (one patient had no preference)).Safety
A total of 341 AEs were reported for 91 (73.4%) of the
124 patients in the safety population. The proportions ofwww.eje-online.org
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Figure 4
(a) Patients with GH control, showing patients with GH levels
%2.5 mg/l at weeks 24 (end of phase 1) and 48 (end of study).
(b) Serum GH levels according to allocated injection schedule
for lanreotide Autogel 120 mg in phase 2. Data are from the
intention-to-treat population. DI, dosing interval; EDI,
extended dosing interval; GH, growth hormone.
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173 :3 320patients experiencing AEs were similar across dosing
interval groups and between phases 1 and 2, and AEs
were mild or moderate in most of these patients (Table 3).
The most common AEs were cholelithiasis (11.3%) and
diarrhoea (10.5%). Fifty-four patients (43.5%) experienced
treatment-related AEs. Eight patients experienced AEs
leading to withdrawal; of these, four patients withdrew
because of AEs considered related to treatment
(one patient experienced diarrhoea, vomiting, dizziness,
aesthenia, dehydration and hyponatraemia; and one
patient in each case experienced stress, flatulence and
migraine). Of 18 serious AEs in 11 patients, six were
considered related to treatment and were all experienced
by the single patient who was withdrawn due to multiple
AEs. One of the other serious AEs (lung cancer) led to
death but was not considered to be related to treatment.www.eje-online.orgGallbladder ultrasound showed that five patients
developed new gallbladder sludge during the study and
eight subjects developed new gallbladder lithiasis during
the study. None of the patients had both new sludge and
new cholelithiasis. There were no clinically relevant
changes for laboratory parameters or vital signs.Discussion
In the LEAD study, high levels of biochemical control were
achieved with lanreotide Autogel 120 mg 6- and 8-week
EDIs in patients with acromegaly who had been previously
well controlled on octreotide LAR 10 or 20 mg every
4 weeks. Specifically, 75.8% of the patients entering the
study and receiving at least one injection of lanreotide
Autogel maintained IGF1 control 48 weeks after switching
to lanreotide Autogel 120 mg EDIs (24 weeks at a 6-week
EDI with a further 24 weeks at a 6- or 8-week EDI).
Moreover, after only 24 weeks of the 6-week EDI (phase 1
of the study), 88.7% of patients maintained IGF1 control.
A favourable IGF1 response to a lanreotide Autogel EDI
was more likely in patients with lower IGF1 levels at
baseline. Most patients were considered to have GH
control, with levels%2.5 mg/l in over 90% of patients at 24
and 48 weeks. Treatmenthad no adverseeffects onsymptom
control or HRQoL, and patient preference for lanreotide
Autogel 120 mg at 4-, 6- or 8-week intervals was higher
than that for octreotide LAR every 4 weeks, particularly
among patients receiving lanreotide at 8-week intervals.
The 120-mg dose of lanreotide was well tolerated during the
study regardless of the injection interval. The most
frequently reported AEs were those typically associated
with somatostatin analogue treatment of acromegaly, and
most were mild or moderate in severity.
The extension of dosing intervals (or dose reductions) is
recommended by the Acromegaly Consensus Group for
patients achieving good biochemical control with long-
acting somatostatin analogues (3). Currently, however,
lanreotide Autogel is the only such agent that has been
approved for use with EDIs, supported by data from initial
open-label studies (14, 15, 19, 20). The LEAD study data add
to this body of published evidence. While the LEAD data are
consistent with findings from earlier trials also involving
patients previously receiving octreotide LAR every 4 weeks,
greater proportions of patients achieved biochemical
control in the LEAD study. In an Italian study of 23 patients
with at least a partial response (in terms of IGF1 and/or GH
levels) to previous treatment with octreotide LAR (10 mg,
nZ2; 20 mg, nZ10; 30 mg, nZ11), patients were assigned
to lanreotide Autogel 120 mg every 4, 6 or 8 weeks based on
Table 3 Adverse events during the study. Data are number (%) of patients from the safety population.
Phase 1 onlya
(6-week EDI; nZ15)
Phase 2
All patients
(nZ124)4-week DI (nZ13) 6-week EDI (nZ70) 8-week EDI (nZ26)
Any AEb 12 (80.0) 10 (76.9) 49 (70.0) 20 (76.9) 91 (73.4)
Related to treatment 7 (46.7) 3 (23.1) 32 (45.7) 12 (46.2) 54 (43.5)
Severe/moderate/mild 5 (33.3)/8 (53.3)/
9 (60.0)
3 (23.1)/3 (23.1)/
9 (69.2)
6 (8.6)/23 (32.9)/
43 (61.4)
3 (11.5)/8 (30.8)/
17 (65.4)
17 (13.7)/42 (33.9)/
78 (62.9)
Leading to withdrawalc 7 (46.7) 0 1 (1.4) 0 8 (6.5)
Any serious AEd 3 (20.0) 2 (15.4) 4 (5.7) 2 (7.7) 11 (8.9)
Related to treatment 1 (6.7) 0 0 0 1 (0.8)
AEs inO10% of patients
Dizziness 3 (20.0) 0 1 (1.4) 0 4 (3.2)
Flatulence 2 (13.3) 0 2 (2.9) 1 (3.8) 5 (4.0)
Constipation 2 (13.3) 0 0 0 2 (1.6)
Cholelithiasis 1 (6.7) 2 (15.4) 7 (10.0) 4 (15.4) 14 (11.3)
Diarrhoea 1 (6.7) 0 11 (15.7) 1 (3.8) 13 (10.5)
Dyslipidaemia 1 (6.7) 0 6 (8.6) 3 (11.5) 10 (8.1)
Headache 1 (6.7) 2 (15.4) 2 (2.9) 2 (7.7) 7 (5.6)
Nasopharyngitis 0 2 (15.4) 3 (4.3) 0 5 (4.0)
Gallbladder polyp 0 2 (15.4) 0 1 (3.8) 3 (2.4)
Osteoarthritis 0 2 (15.4) 0 0 2 (1.6)
Abdominal discomfort 0 1 1 (1.4) 3 (11.5) 4 (3.2)
AE, adverse event; DI, dosing interval; EDI, extended dosing interval.
aPatients from phase 1 not entering phase 2.
bAny AE refers to treatment-emergent AEs; that is, all AEs that occurred during the study.
cNone of the AEs leading to withdrawal occurred in more than one patient; four patients had events leading to withdrawal that were considered to be
related to treatment.
dNo individual serious AEs occurred in more than one patient.
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173 :3 321GH levels after four injections of lanreotide Autogel 120 mg
every 6 weeks (14). Ten patients continued treatment with a
6- or 8-week EDI and the proportions of patients achieving
GH or IGF1 control across dosing-interval groups were
similar at the start compared with the end of the study (after
2–3 doses at the assigned injection interval). In a German
study of 35 patients with normal IGF1 levels (%130% ULN)
while receiving octreotide LAR, patients were assigned to
lanreotide Autogel 120 mg every 8, 6 or 4 weeks initially
according to the previous octreotide LAR dose (10 mg,nZ7;
20 mg, nZ11; 30 mg, nZ17) and then based on IGF1 levels
after the third injection (15). The proportion of patients
maintaining normal IGF1 levels was similar at the start
compared with the end of the study (i.e., after the sixth dose
of lanreotide Autogel). Almost 50% of patients were
successfully treated with lanreotide Autogel EDIs and the
EDIs were associated with increased treatment preference vs
octreotide LAR. The lower proportions of patients main-
taining biochemical control in these two national studies
compared with the LEAD study are probably due, in part, to
the inclusion in the national studies of patients previously
receiving the 30-mg dose of octreotide LAR. These patients
may be less responsive to somatostatin analogues than
patients well controlled on lower octreotide LAR doses and
thus less likely to maintain EDIs. In the LEAD study, lowerbaseline IGF1 levels were generally predictive of a good
biochemical (IGF1) response. This accords well with a
previous study of 51 patients in which IGF1 levels at
baseline were significantly lower in the EDI groups than the
4-week dosing-interval group (20) and generally with data
from the octreotide LAR–lanreotide Autogel switching
studies (14, 15). In contrast to the findings in the LEAD
study, however, some researchers have noted that baseline
GH levels may be predictive of a response to EDIs (19, 20).
Again, the apparently discordant results across studies may
arise from differences in the proportions of poorer
responders in the study cohorts. Poorer responders are
likely to have higher baseline GH (and IGF1) levels and thus
be assigned to 4-week dosing intervals.
Clinical trials suggest EDIs with octreotide LAR may
also be possible with selected patients (21, 22), although
such extended intervals have not been approved and data
are perhaps more limited. In a study involving 13 patients
with normal GH and IGF1 levels while receiving treatment
with octreotide LAR 10 or 20 mg at 4-weekly intervals, the
injection interval was extended to every 6 weeks, with
nine patients maintaining biochemical control (normal
IGF1 levels and GH %2.5 mg/l) after 36 weeks (21). In a
separate study of patients with a mixed treatment history
and active acromegaly, 17 of 19 individuals extendedwww.eje-online.org
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173 :3 322octreotide LAR dosing intervals to every 6, 8, 10 or 12
weeks (16 patients with the 20-mg dose and one with the
30-mg dose) (22). As acknowledged by the authors of the
second study, pretreatment GH levels were relatively low
in their patient cohort; individuals with higher GH levels
may have needed more frequent dosing.
The LEAD study was a large international study
designed to build on previous smaller national studies
and provide robust new data on the profile of patients
most likely to successfully maintain lanreotide Autogel
EDIs in clinical practice. Nonetheless, there are some
limitations that should be noted. First, the large size of the
study made it impractical to assess IGF1 levels with just
one batch of the relevant immunometric assay (Immulite).
Despite this possible source of imprecision for the primary
endpoint, differences between dosing-interval groups were
readily apparent. Second, in accordance with study aims,
patients received the highest approved dose of lanreotide
Autogel (120 mg) and were included only if they had
achieved biochemical control with 10 or 20 mg of
octreotide LAR every 4 weeks. It follows from this that it
cannot be assumed similar results would be obtained with
other doses of the Autogel formulation or with patients
previously achieving biochemical control with the 30-mg
dose of octreotide LAR. While it cannot be ruled out that
some patients may have different responses to different
analogues (13), the requirement for the 30-mg dose of
octreotide LAR suggests a greater resistance to somato-
statin analogues or a biochemically more active tumour
such that there is a lower chance of successfully
maintaining a lanreotide Autogel EDI after switching.
Finally, few patients in the LEAD study were receiving
concomitant dopamine agonists, thus although their
results were encouraging, the suitability of individual
patients receiving combination therapy for lanreotide
Autogel EDIs requires careful clinical assessment. It is
also currently unclear whether the duration of prior
treatment with somatostatin analogues influenced the
likelihood of successfully extending dosing intervals;
further research of this aspect may be warranted.
The LEAD study results suggested that patients with
acromegaly who previously achieved biochemical control
in terms of IGF1 levels while receiving 10 or 20 mg of
octreotide LAR every 4 weeks are likely to be good
candidates for switching to lanreotide Autogel 120 mg
every 6 or 8 weeks. It is important to note baseline IGF1
levels, which may reflect responsiveness to somatostatin
analogues, when considering EDI; patients with baseline
levels below but close to the ULN may be less suitable
candidates who require more careful consideration.www.eje-online.orgAfter five injections every 6 weeks, it would be possible
to determine if an EDI is viable and select the appropriate
extension of the dosing interval. The LEAD study results
also suggested that such patients are likely to maintain
control of IGF1, GH and symptoms for up to at least 1 year
without adverse effects on tolerability or HRQoL. Given
the marked preference for EDIs among patients, EDIs may
improve adherence to treatment. Less frequent dosing
should reduce direct drug costs over time, as well as
alleviating the burdens on patients and HCPs. In addition,
maintenance of similar biochemical control but with
potentially improved patient compliance might have
positive or at least neutral impact on associated co-
morbidities and indirect costs of their management. The
current results, therefore, warrant a full health-economic
analysis of EDIs in different national contexts, taking into
account potential direct and indirect healthcare costs.Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
EJE-15-0215.Declaration of interest
S JCMM Neggers has received research grants and consultancy fees from
Pfizer and Ipsen. V Pronin declares no conflicts of interest. I Balcere has
received research funding from Ipsen. M-K Lee declares no conflicts of
interest. L Rozhinskaya has received lecture fees from Novartis, Ipsen,
Amgen and Eli Lilly, and has participated as a principal investigator in
clinical trials supported by MDS, Novartis, Ipsen and Amgen. M D Bronstein
has been an advisory board member for Ipsen, Novartis, Pfizer and
Chiasma; has been a speaker for Ipsen and Novartis; and has received
research support as principal investigator in clinical trials for Ipsen and
Novartis. M Gadelha has been a speaker for Ipsen, Novartis and Pfizer; has
been an advisory board member for Novartis; has received research
funding from Novartis and Pfizer; and has participated as a principal
investigator in clinical trials for Ipsen and Novartis. P Maisonobe and C Sert
are employees of Ipsen. A J van der Lely has received research grants and
speakers’ and consultancy fees from Novartis, Pfizer and Ipsen.Funding
This work was supported by Ipsen.Author contribution statement
S JCMM Neggers and A J van der Lely were involved in: concept and design
of the study; patient enrolment into the study; analysis, collection and
interpretation of the data; and drafting of the manuscript. P Maisonobe
and C Sert were involved in: analysis and interpretation of the data; and
drafting of the manuscript. V Pronin, I Balcere, M-K Lee, L Rozhinskaya,
M D Bronstein and M Gadelha were involved in: patient enrolment into
the study; collection and interpretation of the data; and critical review
and revision of the paper. All authors approved the final version to be
published and agree to be accountable for all aspects of the work.
E
u
ro
p
e
a
n
Jo
u
rn
a
l
o
f
E
n
d
o
cr
in
o
lo
g
y
Clinical Study S JCMM Neggers and others Extended dosing intervals with
lanreotide
173 :3 323Acknowledgements
We thank the patients, their families and investigators who participated in
this study. We also thank Watermeadow Medical for writing assistance
(funded by Ipsen).
LEAD Study Group: Brazil: M Bronstein, M Gadelha; Denmark: M Andersen;
J O L Jørgensen; Finland: L Niskanen, M Va¨lima¨ki; France: F Archambeaud,
J Bertherat, F Borson-Chazot, R Cohen, B Delemer, A-M Guedj, A Penfornis,
J-L Sadoul, J-L Schlienger, B Verges; Greece: G Krassas, S Tsagarakis, M Tzanela;
Latvia: I Balcere; Norway: E Husebye; Poland: A Baldys-Waligorska,
M Bolanowski, A Kowalska; Romania: C Ghervan; Russia: L Rozhinskaya,
V Pronin; Serbia: S Damjanovic´, M Medic´-Stojanoska, V Popovic´-Brkic´;
South Korea: S-Y Kim, E-J Lee, M-K Lee; Sweden: B Ekman, C Ho¨ybye,
S Karlsson; The Netherlands: S JCMM Neggers, A J van der Lely.References
1 Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH &
Miller KK. American Association of Clinical Endocrinologists medical
guidelines for clinical practice for the diagnosis and treatment of
acromegaly – update. Endocrine Practice 2011 17 (Suppl 4) 1–44.
(doi:10.4158/EP.17.S4.1)
2 Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A,
Sheppard MC, Bates AS & Stewart PM. Mortality in patients with
pituitary disease. Endocrine Reviews 2010 31 301–342. (doi:10.1210/er.
2009-0033)
3 Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR,
Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK et al.
Expert consensus document: a consensus on the medical treatment of
acromegaly. Nature Reviews. Endocrinology 2014 10 243–248.
(doi:10.1038/nrendo.2014.21)
4 Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A &
Wass JAH. Acromegaly: an endocrine society clinical practice guideline.
Journal of Clinical Endocrinology and Metabolism 2014 99 3933–3951.
(doi:10.1210/jc.2014-2700)
5 Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prevost G,
Maisonobe P, Clermont A & PRIMARYS Investigators. Tumor shrinkage
with lanreotide Autogel 120 mg as primary therapy in acromegaly: results
of a prospective multicenter clinical trial. Journal of Clinical Endocrinology
and Metabolism 2014 99 1282–1290. (doi:10.1210/jc.2013-3318)
6 Melmed S, Cook D, Schopohl J, Goth MI, Lam KS & Marek J. Rapid and
sustained reduction of serum growth hormone and insulin-like growth
factor-1 in patients with acromegaly receiving lanreotide Autogel therapy:
a randomized, placebo-controlled, multicenter study with a 52 week open
extension. Pituitary 2010 13 18–28. (doi:10.1007/s11102-009-0191-1)
7 Caron P, Cogne M, Raingeard I, Bex-Bachellerie V & Kuhn JM.
Effectiveness and tolerability of 3-year lanreotide Autogel treatment in
patients with acromegaly. Clinical Endocrinology 2006 64 209–214.
(doi:10.1111/j.1365-2265.2006.02450.x)
8 Holdaway IM, Bolland MJ & Gamble GD. A meta-analysis of the effect
of lowering serum levels of GH and IGF-I on mortality in acromegaly.
European Journal of Endocrinology 2008 159 89–95. (doi:10.1530/
EJE-08-0267)
9 Salvatori R, Nachtigall LB, Cook DM, Bonert V, Molitch ME, Blethen S,
Chang S & SALSA Study Group . Effectiveness of self- or partner-
administration of an extended-release aqueous-gel formulation of
lanreotide in lanreotide-naive patients with acromegaly. Pituitary 2010
13 115–122. (doi:10.1007/s11102-009-0207-x)10 Salvatori R, Woodmansee WW, Molitch M, Gordon MB & Lomax KG.
Lanreotide extended-release aqueous-gel formulation, injected by
patient, partner or healthcare provider in patients with acromegaly in
the United States: 1-year data from the SODA registry. Pituitary 2014 17
13–21. (doi:10.1007/s11102-012-0460-2)
11 Adelman DT, Liebert KJ, Nachtigall LB, Lamerson M & Bakker B.
Acromegaly: the disease, its impact on patients, and managing the
burden of long-term treatment. International Journal of General Medicine
2013 6 31–38. (doi:10.2147/IJGM.S38594)
12 Adelman DT, Burgess A & Davies PR. Evaluation of long-acting
somatostatin analog injection devices by nurses: a quantitative study.
Medical Devices 2012 5 103–109. (doi:10.2147/MDER.S37831)
13 Troconiz IF, Cendros JM, Peraire C, Ramis J, Garrido MJ, Boscani PF &
Obach R. Population pharmacokinetic analysis of lanreotide Autogel in
healthy subjects: evidence for injection interval of up to 2 months.
Clinical Pharmacokinetics 2009 48 51–62. (doi:10.2165/0003088-
200948010-00004)
14 Ronchi CL, Boschetti M, degli Uberti EC, Mariotti S, Grottoli S, Loli P,
Lombardi G, Tamburrano G, Arvigo M, Angeletti G et al. Efficacy of a
slow-release formulation of lanreotide (Autogel) 120 mg) in patients
with acromegaly previously treated with octreotide long acting release
(LAR): an open, multicentre longitudinal study. Clinical Endocrinology
2007 67 512–519. (doi:10.1111/j.1365-2265.2007.02917.x)
15 Schopohl J, Strasburger CJ, Caird D, Badenhoop K, Beuschlein F,
Droste M, Plo¨ckinger U, Petersenn S & German Lanreotide Study
Group. Efficacy and acceptability of lanreotide Autogel(R) 120 mg at
different dose intervals in patients with acromegaly previously treated
with octreotide LAR. Experimental and Clinical Endocrinology & Diabetes
2011 119 156–162. (doi:10.1055/s-0030-1267244)
16 Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA,
Badia X, Webb SM & van der Lely AJ. Quality of life in acromegalic
patients during long-term somatostatin analog treatment with and
without pegvisomant. Journal of Clinical Endocrinology and Metabolism
2008 93 3853–3859. (doi:10.1210/jc.2008-0669)
17 Webb SM, Badia X & Surinach NL. Validity and clinical applicability of
the acromegaly quality of life questionnaire. AcroQoL: a 6-month
prospective study. European Journal of Endocrinology 2006 155 269–277.
(doi:10.1530/eje.1.02214)
18 Ware JEJ, Kosinski M, Bjorner JB, Tuner-Bowker DM, Gandek B &
Maruish ME. User’s Manual for the SF-36v2(R) Health Survey, 2nd edn.
Lincoln, RI: QualityMetric, Incorporated, 2007.
19 Lucas T & Astorga R. Efficacy of lanreotide Autogel administered every
4–8 weeks in patients with acromegaly previously responsive to
lanreotide microparticles 30 mg: a phase III trial. Clinical Endocrinology
2006 65 320–326. (doi:10.1111/j.1365-2265.2006.02595.x)
20 Lombardi G, Minuto F, Tamburrano G, Ambrosio MR, Arnaldi G,
Arosio M, Chiarini V, Cozzi R, Grottoli S, Mantero F et al. Efficacy of the
new long-acting formulation of lanreotide (lanreotide Autogel) in
somatostatin analogue-naive patients with acromegaly. Journal of
Endocrinological Investigation 2009 32 202–209. (doi:10.1007/
BF03346453)
21 Biermasz NR, van den Oever NC, Frolich M, Arias AM, Smit JW,
Romijn JA & Roelfsema F. Sandostatin LAR in acromegaly: a 6-week
injection interval suppresses GH secretion as effectively as a 4-week
interval. Clinical Endocrinology 2003 58 288–295. (doi:10.1046/
j.1365-2265.2003.01710.x)
22 Turner HE, Thornton-Jones VA & Wass JA. Systematic dose-extension
of octreotide LAR: the importance of individual tailoring of treatment
in patients with acromegaly. Clinical Endocrinology 2004 61 224–231.
(doi:10.1111/j.1365-2265.2004.02084.x)Received 23 February 2015
Revised version received 5 May 2015
Accepted 5 June 2015www.eje-online.org
